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Background: Follistatin (Fst) promotes brown adipocyte characteristics in adipose tissues.
Methods: Abdominal fat volume (CT scan), glucose clearance (GTT test), and metabolomics 
analysis (mass spectrometry) of adipose tissues from Fst transgenic (Fst-Tg) and wild type 
(WT) control mice were analyzed. Oxygen consumption (Seahorse Analyzer) and lipidomics 
(gas chromatography) was analyzed in 3T3-L1 cells.
Results: Fst-Tg mice show significant decrease in abdominal fat content, increased glucose clear-
ance, improved plasma lipid profiles and significant changes in several conventional metabolites 
compared to the WT mice. Furthermore, overexpression of Fst in 3T3-L1 cells resulted in up 
regulation of key brown/beige markers and changes in lipidomics profiles. 
Conclusion: Fst modulates key factors involved in promoting metabolic syndrome and could 
be used for therapeutic intervention.
Keywords: follistatin, transgenic, adipocyte, fibroblast growth factor 21, AdipoQ
Introduction
Follistatin (Fst) binds several members of the transforming growth factor-β super-
family including activins and Mst to neutralize their biological activities.1–3 Several 
genetic studies have demonstrated an essential role for Fst in skeletal muscle devel-
opment3–6; however, the role of Fst in other metabolic tissues is poorly understood. 
Fst KO pups die just after birth due to defects in musculoskeletal system4 making it 
difficult to assess the functional role of Fst in other metabolically relevant tissues. 
We utilized MEF cultures from WT and Fst KO embryos and analyzed differentially 
expressed genes and proteins.7 We demonstrated that Fst promotes “browning” of 
adipocytes, increases cellular bioenergetics through increased expression of mark-
ers for brown adipose, FA oxidation and mitochondrial markers.7 More recently, 
we have demonstrated that Fst-Tg mice have increased expression of BAT-specific 
proteins in both Epi and SC WAT and BAT when compared to WT mice. While Fst 
targets Myf5+ cells in BAT, it promotes phosphorylation of p38MAPK and ERK1/2 
in WAT to promote adipose browning.8 Activation of white adipose browning pro-
gram plays a critical role in positively regulating overall systemic metabolism as 
Epi and SC adipose tissues are the main site of energy storage and mobilization.9–13 
Biochemical changes occurring during adipose browning are linked with alteration 
in several metabolic pathways.14–15 We therefore sought to determine whether Fst 
expression regulates (in addition to browning) the metabolic repertoire of adipocytes 
and adipose tissues.
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Emerging technologies developed in recent years have 
allowed high-throughput profiling of various metabolites 
from blood and tissue specimens and have been help-
ful in predicting the risk for several diseases.16–18 These 
metabolites are particularly relevant for studying metabolic 
diseases and for prediction of potential biomarkers. Metabo-
lomics and principal component analysis have identified 
several key metabolites that showed strongest difference 
between obese and lean groups and are strong predictors 
of metabolic conditions including insulin resistance and 
glucose intolerance.17
In this study, we have performed comprehensive metabo-
lomics profiling of Epi and SC adipose tissues isolated from 
WT and Fst-Tg mice to identify key metabolites that are 
differentially present in these tissues and correlated their 
functional role in regulating various metabolic parameters. 
We demonstrated, for the first time, that Fst overexpression 
in Fst-Tg mice and in differentiating 3T3-L1 cells favorably 
alters key metabolites including BCAA and their catabolic 
pathways, carbohydrates, and lipoprotein profiles. We have 
further demonstrated that in both Tg adipose tissues and 
in differentiating 3T3-L1 cell culture models, Fst targets 
AdipoQ/FGF21/pAMPK axis which has been implicated 
as a key regulator of metabolic syndrome. Collectively, our 
data suggest that Fst favorably influences key adipose tissue 
metabolites and suggest a therapeutic role for Fst in the treat-
ment of obesity and related metabolic conditions.
Materials and methods
animals used and tissue collection
Fst-Tg expressing Fst under the control of a skeletal muscle-
specific myosin light chain promoter/enhancer3 were used for 
our experiments. Since Fst transgene in Fst-Tg was found 
to be on Y chromosome,3 all experiments were performed 
using male Fst-Tg mice and age matched control mice. Food 
consumption was monitored in alternate days and body 
weights were measured every week. Epi and SC WAT were 
harvested from 5 week’s old Fst-Tg and WT (C57BL6/J) male 
mice.3 Mice were housed at a constant temperature (68°F) 
under artificial light/dark cycle (12 h/12 h) and allowed to 
have free access to water and food. The Charles R Drew 
University of Medicine and Science Institutional Animal 
Care and Use and Committee approved all animal experi-
ments that were conducted by following the guidelines of 
United States Department of Agricultural Animal Care and 
Animal Welfare Act.
cT scan
Abdominal fat volume of WT and Fst-Tg mice were ana-
lyzed using MicroCAT II small animal CT system (Siemens 
Preclinical Solutions, Knoxville, TN, USA) and freely 
available software AMIDE (http://amide.sourceforge.
net/) as previously described by Suckow and Stout19 and 
Wang et al.20 
glucose tolerance test
Four weeks old male WT and Fst-Tg mice were fasted 
overnight and anesthetized with an IP injection of sodium 
pentobarbitone (100 mg/kg). A silastic catheter filled with 
heparinized saline (20 µ/ml) was inserted into left carotid 
artery. A bolus of glucose (1g/kg body weight) was injected 
into the IP cavity. 25 µl of blood was collected at 0, 30, 
60, 120, 180, and 240 minutes for plasma glucose using 
HemoCue Glucose 201 analyzer (Ängelholm, Sweden) 
analysis. 
Serum analysis
Serum levels of TG, FFA, TC and HDL were determined 
by enzymatic colorimetric assays as described previously.21 
Cloning of full-length mouse Fst into 
Piggyback vector and generation of Fst by 
overexpressing 3T3-L1 cell line
Full-length mouse Fst (NM_008046) was cloned into Pig-
gyback Transposon cargo plasmid vector (Transposagen Inc.) 
and the sequence was verified. 3T3-L1 cells were transfected 
with Piggyback transposon containing CMV-Fst PuroTK 
along with the piggyback transposase, using standard trans-
fection techniques (Figure S1A). The Piggyback transposase 
recognizes PB transposon sequence (IRT’s), cuts transposon 
carrying Fst out of the plasmid, and integrates it stably in the 
genome. Stable clones were selected in presence of 10 µg/ml 
puromycin. Confirmation of the puromycin resistant Fst over-
expressing 3T3-L1 cells (3T3-L1 Fst) in PiggyBac backbone 
was performed by PCR analysis of the genomic DNA using 
T7 forward (1268–1283) and Fst reverse (2141–2121) primer 
sets (Figure S1B). Both control 3T3-L1 and 3T3-L1 Fst cells 
were allowed to differentiate under standard differentiation 
conditions for 6–9 days.8,22
real-time quantitative Pcr analysis
Gene expression analysis was performed using 2 µg of 
total RNA that were reverse transcribed using RNA High 
 
D
ia
be
te
s,
 M
et
ab
ol
ic 
Sy
nd
ro
m
e 
an
d 
O
be
sit
y:
 T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
64
.1
47
.4
8.
86
 o
n 
14
-A
pr
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
67
Fst therapy for metabolic diseases
Capacity cDNA kit (Applied BioSystems, Foster City, CA, 
USA). The Power SYBR Green PCR master mix was used 
with 7500 fast real-time PCR system (Applied BioSystems). 
Gene-specific primer pairs were designed and experimental 
mRNA starting quantities were calculated from the standard 
curves and averaged using 7500 software v1.4 as previously 
described.7,8,23
immunoblot analysis
Total cellular proteins (50–100 µg) were resolved on sodium 
dodecyl sulfate-polyacrylamide gels (10–15%), electro-
transferred on polyvinylidene difluoride membranes and 
analyzed using the following antibodies-anti-Fst (1:1,000 
dilutions, cat# ab64490; Abcam, Cambridge, MA, USA), 
anti-UCP1 (1:1,000 dilutions, cat# 10983; Abcam), p38 
MAPK (1:1,000 dilutions, cat# 92125; Cell Signaling, 
MA, USA), anti-pp38 MAPK (1:1,000 dilutions, cat# 
92115; Cell Signaling), anti-ERK1/2(1:1,000 dilutions, cat# 
91025; Cell Signaling), anti-pERK1/2 (1:1,000 dilutions, 
cat# 91015; Cell Signaling), anti-COX-IV (1:1,000 dilu-
tion, cat# ab14744; Abcam), anti-SirT1 (1:1,000 dilution, 
cat# ab110304; Abcam), anti-SirT3 (1:1,000 dilution, cat# 
ab86671; Abcam), anti-BCAT2 (1:1,000 dilutions, cat# 
ab95976; Abcam); anti-BCKDHA (1:1,000 dilutions, cat# 
ab90691; Abcam); anti-AdipoQ (1:1,000 dilutions, cat# 
MAB 1119; R & D Systems); anti-AMPK/anti-pAMPK 
(1:1,000 dilutions, cat# 2532; 2535; Cell Signaling); 
anti-FGF21 (1:1,000 dilutions, cat# MAB25371; R & D 
Systems); anti-PGC-1α (1: 1,000 dilution, cat# ab54481; 
Abcam), anti-AdipoR1 (1: 1,000 dilution, cat# sc99183; 
Santa Cruz Biotech, Dallas, TX, USA), and anti-Mup1 
(1: 1,000 dilution, cat# sc66976; Santa Cruz Biotech), 
anti-β-actin (1:5,000 dilutions, cat# sc-81178; Santa Cruz 
Biotech) or anti-GAPDH (1:5,000 dilutions, cat# MAB374; 
Millipore) antibodies with secondary antibodies (1:1,000 
dilution) linked to horseradish peroxidase (Cell Signal-
ing). Immunopositive bands were scanned and analyzed 
as described before.7,8 
Analysis of cellular oxygen consumption
OCR of cells (4 × 104 cells per well) were analyzed in a XF24 
Extracellular Flux Analyzer (Seahorse Bioscience Inc., North 
Billerica, MA, USA) as previously described.7 
lipidomics analysis
Analysis of various lipids in differentiated 3T3-L1 control 
and Fst overexpressing 3T3-L1-Fst cells were performed 
using gas chromatography time-of-flight technology plat-
form at UC Davis Metabolomics Core Laboratory (http://
metabolomics.ucdavis.edu/core-services/metabolomics-
central-service-core). The workflow involves sample extrac-
tion in methyl tert-butyl ether with addition of internal 
standards, followed by ultra-high pressure liquid chroma-
tography on a Waters CSH column, interfaced to a quad-
rupole–time-of-flight mass spectrometer (high resolution, 
accurate mass), with a 15 minute total run time. Peak areas 
of lipid species within the range of calibration curves were 
analyzed by comparing the individual peak areas with those 
of corresponding internal standards for determining the 
final concentrations. Data were collected in both positive 
and negative ion mode and analyzed using MassHunter 
(Agilent). Approximately 400 lipids species including 
mono-, di-, and triacylglycerols, glycerophospholipids, 
sphingolipids, cholesterol esters, ceramides, and FAs can 
be identified from plasma, with additional unknowns. The 
method is highly stable and has been validated on large 
datasets (>8,000 samples) collected over long time periods 
(>1 year).24
Metabolomic and statistical analysis
Entire metabolomics analysis of Epi and SC adipose tissues 
from WT and Fst-Tg mice was performed at Metabolon Inc 
(Morrisville, NC, USA) (www.metabolon.com). Samples 
were prepared using the automated MicroLab STAR® system 
from Hamilton Company and processed either with liquid 
chromatography/mass spectrometry or gas chromatography/
mass spectrometry as described before.25 Accurate mass 
determination, compound identification, bioinformatics, and 
statistical analysis (R, version 2.6.0, http://www.r-project.
org/ and SPSS for Windows version PASW 17.0; SPSS Inc: 
Chicago, USA) were done by Metabolon Inc. essentially as 
described before.25
general statistical analysis
Data are presented as mean ± SD. Differences between the 
groups were analyzed by ANOVA using GraphPad Prism 
Version 5.3 (GraphPad Software, San Diego, CA, USA). If 
the overall ANOVA revealed significant differences, then 
pair-wise comparisons between groups were performed by 
Newman-Keuls multiple group test. All comparisons were 
two-tailed and P-values ≤ 0.05 were considered statisti-
cally significant. The experiments were repeated at least 
three times, and data from representative experiments are 
shown.25
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Results 
Fst-Tg mice have decreased abdominal fat 
volume, increased glucose clearance and 
improved serum lipid profiles
We recently demonstrated that adipose browning of Epi 
and SC WAT is increased in Fst-Tg mice.8 To test whether 
increased adipose browning in Fst-Tg mice tissues alters 
their abdominal fat mass, we performed CT scans of 6 
weeks old WT and Fst-Tg male mice fed a normal chow 
diet. Weekly food consumption was significantly decreased 
(11.3%; P≤0.05) in Fst-Tg mice compared to the WT 
mice (Figure 1A). Fst-Tg mice had higher body weights 
(24.8±1.7 g vs. 18.5±1.1 g) compared to the WT (Figure 1B) 
because of significant increase in muscle mass as previously 
reported.3 Analysis of fat content by quantitative analysis of 
CT scans showed significantly lower percentage of abdomi-
nal fat in Fst-Tg mice (15.2±3.6%) compared to the WT 
(28.4±6.2%) mice (Figure 1C and D). Comparative analysis 
of whole body glucose disposal in fasting Fst-Tg and WT 
mice by glucose tolerance test after IP injection of glucose 
(1 g/kg) showed a significant decrease in glucose levels after 
1 and 2 hours, but no significant difference in subsequent 
time points (3–4 h) (Figure 1E). Comparison of serum 
TG, TC, HDL, FFA, and glucose levels show significantly 
decreased levels of TG, UC, FFA and glucose in Fst-Tg 
mice compared to the WT mice (Figure 1F). However, the 
changes in TC and HDL levels were not significantly altered 
between the groups. Mup1 is a key regulator of glucose 
and lipid metabolism,26 and increases energy expenditure 
through enhanced mitochondrial function.27 We have previ-
ously identified Mup1 as an Fst-inducible gene7 and in this 
study, we show that Mup1 gene and protein expression are 
upregulated in liver tissues isolated from WT and Fst-Tg 
mice (Figure S2A–D), suggesting a potential role for Mup1 
in Fst-mediated metabolic changes. These data collectively 
suggest that Fst upregulation in distant muscle tissues could 
affect whole body metabolism through increased systemic 
levels of Fst as reported previously by our group.8
Differentiated 3T3-L1 cells 
overexpressing Fst have significantly 
higher levels of key adipose browning 
markers and increased maximum OCRs 
We cloned the full-length mouse Fst gene into Piggyback 
Transposon cargo plasmid vector (Transposagen Inc.) 
and generated 3T3-L1 Fst stable cell line as described in 
the “Materials and methods” section. Cellular Fst protein 
content (Figure 2A), Fst gene expression (Figure 2B) and 
secreted Fst in cell culture supernatants (Figure 2C) were 
all significantly higher in 3T3-L1 Fst cells compared to the 
control 3T3-L1 cells. Next, we performed a comprehensive 
gene expression analysis in 3T3-L1 Fst and 3T3-L1 cells 
that were allowed to differentiate under standard adipogenic 
differentiation conditions for 9 days. Key beige adipocyte-
related genes including Cd137, Tmem26, Tbx1, Th, and 
Ptgs2a, mitochondrial markers Ucp1, Cox7a1, Cox8b, and 
Cpt1a and other key genes implicated in regulating overall 
energy and lipid metabolism including Fgf21, Bmp7, and 
Pgc1a were all significantly increased in 3T3-L1 Fst cells 
compared to 3T3-L1 cells (Figure 2D). Fasn, a key lipogenic 
marker, and Mst levels were also significantly decreased in 
3T3-L1 Fst cells (Figure 2D). Moreover, key beige-related 
proteins (UCP1, Cd137), mitochondrial protein (COX-IV) 
along with AdipoQ and SirT-1 and -3 (Figure 2E) were also 
significantly increased in 3T3-L1 Fst cells, underscoring the 
role of Fst in adipose browning and regulation of energy 
metabolic pathways. Furthermore, two key signaling path-
ways implicated in adipose browning p38 MAP kinase and 
ERK1/2 phosphorylation,8 were upregulated in differenti-
ated 3T3-L1 Fst cells compared to the 3T3-L1 cells (Figure 
2E). Analysis of OCR further suggest significant increase 
(~62%) in maximal OCR in 3T3-L1 Fst cells compared to 
3T3-L1 cells undergoing adipogenic differentiation (Figure 
2F), suggesting increased mitochondrial biogenesis. Taken 
together, our results in cell culture and mice show that Fst 
is a potent inducer of browning related signaling pathways 
and may influence overall energy and lipid metabolism. 
Analysis of lipidomic profiles of 
differentiated 3T3-L1 Fst and 3T3-L1 
cells 
To test the effect of Fst overexpression on various endogenous 
lipid metabolites, we performed lipid profiling of day 9 differ-
entiated cells. There was a general reduction in diglycerides, 
TG; ceramide (d42:0), FA, PC, PE, lysophosphatidylethanol-
amine (16:0), and LPC (16:1) levels in differentiated 3T3-L1 
Fst cells compared to the control 3T3-L1 cells (Table 1). 
On the other hand, we found significant increase in several 
LPCs including LPC (16:0), LPC (18:0), and LPC (18:1) in 
3T3-L1 Fst cells in comparison to 3T3-L1 cells (Table 1). 
Ceramide (d42:0) was found to be significantly decreased in 
3T3-L1 Fst cells compared to the control 3T3-L1 cells. Our 
cell culture data, therefore, suggest that Fst overexpression 
in 3T3-L1 Fst cells favorably alters overall lipid profiling by 
1) decreasing lipid metabolites known to contribute toward 
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Figure 1 Analysis of abdominal fat volume, glucose clearance, and serum profiles of WT and Fst-Tg mice. (A) Analysis of weekly total food consumption, (B) body weight, 
(C) abdominal fat volume by CT-scan, and (D) quantitative analysis of abdominal fat volume in 10 week-old male WT and Fst-Tg mice fed on normal chow. (E) glucose 
tolerance test (GTT), 10-week-old male WT and Fst-Tg mice were fasted overnight and given D-glucose (1 g/kg) by IP injection. Blood glucose was measured at different 
time points. (F) Analysis of serum profiles of 10-week-old WT and Fst-Tg mice. Data are expressed as mean ± SD. *P≤0.05, **P≤0.01 (n=10).
Abbreviations: WT, wild type; Fst-Tg, follistatin transgenic; TG, triglyceride; HDL. high-density lipoprotein; UC, unesterified cholesterol; FFA, free fatty acid.
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Figure 2 Comparative analysis of Fst expression, key brown/beige related markers and oxygen consumption in Fst overexpressing 3T3-L1 Fst and 3T3-L1 cells. Analysis of 
relative Fst protein (A), gene expression (B), and Fst release in cultured medium (30 µl supernatant) (C) in 3T3-l1 and 3T3-l1 Fst grown under normal growth conditions. 
(D) Quantitative gene expression analysis of key markers involved in adipose browning, mitochondrial biogenesis pathway in cells allowed to differentiate under standard 
adipogenic differentiation conditions for 9 days. (E) Western blot analysis of key proteins involved in adipose browning and regulation of key signaling pathway involved during 
the process in differentiated 3T3-L1 and 3T3-L1 Fst cells. (F) Analysis of OCR in differentiated 3T3-L1 and 3T3-L1 Fst cells after 9 days using Seahorse Bioscience XF24 
extracellular flux analyzer. Data are expressed as mean ± SD. *P≤0.05, **P≤0.01, and ***P≤0.001. (n=3).
Abbreviations: Fst, follistatin; GADPH, glyceraldehyde 3-phosphate dehydrogenase; OCR, oxygen consumption rate; UCP, uncoupling protein; MAPK, mitogen-activated 
protein kinase; ERK, extracellular-signal-regulated kinase; COX, cyclooxygenase; SirT, sirtuin; AdipoQ, adiponectin.
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development of obesity and related metabolic diseases28,29 and 
2)  significantly increasing several LPCs which are reported to 
be reduced in obesity and type 2 diabetes associated change 
in body fat mass.30,31
Metabolomics profiling of Epi and SC 
adipose tissues from Fst-Tg and WT 
control mice 
Adipose tissue, a key endocrine organ, has been widely 
implicated not only in the regulation of glucose and lipid 
homeostasis but also plays an important role in systemic 
protein and amino acid metabolism. Next, we have per-
formed comprehensive metabolomics analysis of adipose 
tissues isolated from 6-week-old male WT and Fst-Tg mice. 
We have also analyzed adipose tissue for our metabolomics 
analysis to avoid possible confounding effects of secreted 
Fst produced from muscle tissues in these Fst-Tg mice. We 
observed significant differences in key metabolites includ-
ing amino acids, components of FA and carnitine metabo-
lism, carbohydrates, and nucleotides as well as some other 
chemicals and cofactors (Tables 2 and 3). These differences 
in various metabolites between WT and Fst-Tg were more 
prominent in Epi (Table 2) compared to the SC adipose 
tissues (Table 3). 
energy and lipid metabolism
Comparative analysis of metabolites involved in energy and 
lipid metabolism in the two adipose tissue depots from WT 
and Fst-Tg mice display significant differences between the 
groups. Krebs cycle components including citrate, succinyl-
carnitine, and fumarate were significantly downregulated in 
Fst-Tg Epi tissues compared to the WT tissues (Table 2), 
whereas, only succinate was found to be downregulated in 
Fst-Tg SC adipose tissues compared to the WT (Table 3). 
Phosphate levels were significantly decreased in both Fst-Tg 
Epi and SC tissues. Significant decreases in several long chain 
FA levels were observed in both adipose tissues obtained from 
Fst-Tg group; however, the differences in medium chain FA 
levels were observed only in Epi adipose tissues. Compara-
tive analysis of several components of carnitine metabolism 
display significant decrease in acetylcarnitine and propionyl-
carnitine levels in both adipose depots. However, there was 
also significant decrease in other carnitine metabolites (car-
nitine, 3-dehydroxycarnitine, butyrylcarnitine), and ketone 
bodies (3-hydroxybutyrate) selectively in Epi adipose tissue 
(Table 2). Glycerolipid levels were also significantly lower in 
Fst-Tg groups. Levels of several lysolipids were also found 
to be significantly lower in Fst-Tg groups compared to the 
Table 1 Lipidomics profiling of differentiated 3T3-L1 and 3T3-L1 
Fst cells by gas chromatography time-of-flight (n=8).
Compound P value Ratio (3T3-L1 Fst vs. 
3T3-L1)
Dg (34:1) 0.0341 0.4
Dg (36:2) 0.0354 0.3
Pc (32:1) 0.0306 0.32
Pc (32:2) 0.0485 0.03
TG (14:0/14:0/14:0) 0.0154 0.07
Tg (46:1) 0.0171 0.014
Tg (46:2) 0.0218 0.014
Tg (46:2) 0.0032 0.004
Tg (46:3) 0.0031 0.004
Tg (48:1) 0.0536 0.11
Tg (48:2) 0.02 0.01
Tg (48:3) 0.0042 0.004
Tg (49:1) 0.0002 0.08
Tg (49:3) 0.0019 0.02
Tg (50:2) 0.0081 0.03
Tg (50:4) 0.0099 0.015
Tg (51:2) 0.013 0.083
Tg (51:3) 0.0063 0.05
Tg (52:3) 0.0036 0.038
Tg (53:2) 0.0328 0.13
Tg (53:3) 0.0437 0.122
Tg (54:1) 0.0052 0.136
Tg (54:2) 0.0492 0.154
Tg (54:5) 0.032 0.45
Tg (54:6) 0.0177 0.154
Tg (56:1) 0.0143 0.18
Tg (56:2) 0.0042 0.08
Tg (56:3) 0.0184 0.1
Tg (56:7) 0.0166 0.29
Tg (58:1) 0.0068 0.33
Tg (58:2) 0.0022 0.2
Tg (58:3) 0.0049 0.21
Tg (60:2) 0.007 0.37
ceramide (d42:0) 0.0436 0.59
Fa (14:1) 0.0027 0.06
Fa (17:1) 0.0009 0.29
Fa (18:1) 0.028 0.37
Fa (18:3) 0.0121 0.83
lPe (16:0) 0.0008 0.24
Pc (32:2) 0.0006 0.02
Pc (33:1) 0.0001 0.22
Pc (33:2) 4.64e–06 0.25
Pc (34:2) 0.0111 0.2
Pc (34:3) 0.0166 0.36
Pe (34:1) 0.019 0.03
Pe (36:2) 0.0154 0.4
Pe (p-34:1) or Pe (0-34:2) 0.0083 0.4
Pe (p-34:2) or Pe (0-34:3) 0.0091 0.08
lPc (16:0) 1.64e–05 5.16
lPc (18:0) 2.77e–06 9.12
lPc (18:1) 0.0019 2.81
lPc (0–16:0) 5.55e–08 14.5
lPc (p-16:0) 1.82e–06 9.9
lPc (p18:0) 0.0006 53.1
Abbreviations: DG, diacylglycerols; TG, triglyceride; FA, fatty acids; PC, phosphat- 
idylcholines; Pe, phosphatidylethanolamines; lPe, lysophosphatidy-lethanolamine; lPc, 
lysophosphatidylcholine. 
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WT (Tables 2 and 3). Interestingly, cholesterol levels were 
selectively lower only in Epi adipose tissues.
amino acids 
Several key amino acids involved in alanine and aspartate 
metabolism (asparagine), glutamate metabolism (glutamate) 
gamma-methyl ester, tyrosine, tryptophan metabolism, 
valine, leucine and isoleucine metabolism, cysteine, methio-
nine, taurine metabolism as well as several key components 
of urea cycle metabolism including arginine, ornithine, 
proline, citrulline, and trans-4-hydroxyproline were sig-
nificantly downregulated in Fst-Tg Epi adipose tissues 
compared to the WT (Table 2). On the other hand, SC adi-
pose tissues displayed a significant but only a less dramatic 
decrease in certain amino acids including alanine, 3-indoxyl 
sulfate, and hydroxyisovaleroyl carnitine (Table 3). The 
levels of beta-alanine however was significantly increased 
in Fst-Tg SC adipose tissues compared to the WT control 
group (Table 3). Levels of 3-indoxyl sulfate, a key trypto-
phan metabolism component known to be upregulated in 
diabetic patients,25 was also found to be significantly lower 
in SC adipose depots of Fst-Tg mice (Table 3). However, in 
both adipose tissue depots, a general trend toward decreased 
amino acid levels were observed in Fst-Tg group compared 
to the WT group. Interestingly, several of these metabolites 
including BCAA (leucine, isoleucine, and valine) are known 
to be significantly induced in obese subjects compared to 
the lean humans and contribute to increased risk of type 2 
diabetes insulin resistance in humans and in some rodent 
models.16–18, 32–36
carbohydrates
In our metabolomics analysis, we observed several carbohy-
drate metabolites including maltose, mannose 6-phosphate, 
glucose-6-phosphate, fructose-6-phosphate, lactate as well 
as 3-phosphoglycerate were significantly lower in Fst-Tg 
groups compared to the WT (Tables 2 and 3). We also found 
significantly decreased levels of several purine metabolism 
components including xanthine/hypoxanthine, inosine, 
3′-AMP, cytidine, uracil, guanosine, and adenine in Fst-Tg 
groups (Tables 2 and 3). Levels of several other metabolites 
including nicotinamide, pantothenate, and benzoate as well 
as xenobiotics such as glycerol 2-phosphate and equol sulfate 
were selectively decreased in Epi adipose tissues obtained 
from Fst-Tg groups compared to the WT group (Table 2). On 
the other hand, levels of stachydrine/homostachydrine were 
Table 2 Metabolomics analysis (Metabolon Inc.) of Epi adipose tissues obtained from 6 weeks old WT and Fst-Tg mice showing relative 
differences in various metabolites involved in the regulation of key metabolic pathways (n=3).
Super pathway Sub pathway Biochemical name Platform Fst-Tg vs WT-Epi
 (fold; P-value)
 Mass
amino acids alanine and aspartate metabolism asparagine LC/MS pos 0.62 (P=0.03) 133.1
glutamate metabolism glutamate gamma-methyl ester LC/MS pos 0.68 (P=0.03) 162.1
Tyrosine metabolism Tyrosine LC/MS pos 0.48 (P=0.04) 182.1
Tryptophan metabolism c-glycosyltryptophan LC/MS pos 0.64 (P=0.01) 367.1
3-indoxyl sulfate LC/MS pos 0.27 (P=0.02) 212
Valine, leucine, and isoleucine 
metabolism
isoleucine LC/MS pos 0.47 (P=0.04) 132.1
3-hydroxyisobutyrate GC/MS 0.61 (P=0.01) 177.11
isobutyl carnitine LC/MS pos 0.36 (P=0.02) 232.2
isovalerylcarnitine LC/MS pos 0.21 (P=0.01) 246.2
Hydroxyisovaleroyl carnitine LC/MS pos 0.56 (P=0.002) 262.1
cysteine, methionine, SaM, and 
taurine metabolism
hypotaurine GC/MS 0.35 (P=0.04) 188
Methionine LC/MS pos 0.55 (P=0.01) 150.1
n-acetyl methionine LC/MS neg 0.47 (P=0.02) 190.1
Urea cycle; arginine, and proline 
metabolism
arginine LC/MS pos 0.73 (P=0.01) 175.2
Ornithine GC/MS 0.41 (P=0.04) 141.9
Proline LC/MS pos 0.64 (P=0.01) 116.1
citrulline LC/MS pos 0.6 (P=0.01) 176.1
Trans-4-hydroxyproline GC/MS 0.35 (P=0.02) 140
(Continued)
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Super pathway Sub pathway Biochemical name Platform Fst-Tg vs WT-Epi
 (fold; P-value)
 Mass
carbohydrate Fructose, mannose, galactose, 
starch, and sucrose metabolism
Maltose GC/MS 0.21 (P=0.04) 204.1
Mannose-6-phosphate GC/MS 0.32 (P=0.02) 387.2
glucose-6-phosphate (g6P) GC/MS 0.29 (P=0.001) 387.2
Fructose-6-phosphate GC/MS 0.25 (P=0.01) 315.1
lactate GC/MS 0.45 (P=0.03) 116.9
energy Krebs cycle citrate GC/MS 0.57 (P=0.03) 273.1
Succinylcarnitine LC/MS pos 0.44 (P=0.001) 262.1
Fumarate GC/MS 0.68 (P=0.04) 245
Oxidative phosphorylation Phosphate GC/MS 0.46 (P=0.02) 298.9
Medium chain fatty acid caproate (6:0) LC/MS neg 0.56 (P=0.03) 115.2
caprate (10:0) LC/MS neg 0.26 (P=0.008) 171.2
laurate (12:0) LC/MS neg 0.24 (P=0.03) 199.3
Long chain fatty acid Myristate (14:0) LC/MS neg 0.52 (P=0.04) 227.3
Myristoleate (14:1n5) LC/MS neg 0.4 (P=0.0002) 225.3
arachidonate (20:4n6) LC/MS neg 0.75 (P=0.03) 303.4
Fatty acid metabolism (also BCAA 
metabolism)
Propionylcarnitine LC/MS pos 0.65 (P=0.02)) 218.2
Butyrylcarnitine LC/MS pos 0.29 (P=0.01) 232.2
carnitine metabolism carnitine LC/MS pos 0.47 (P=0.02) 162.2
3-dehydrocarnitine LC/MS pos 0.43 (P=0.04) 160.2
acetylcarnitine LC/MS pos 0.57 (P=0.005) 204.2
choline phosphate LC/MS pos 0.59 (P=0.01) 184.1
glycerolipid metabolism glycerol GC/MS 0.6 (P=0.005) 205
Ketone bodies 3-hydroxybutyrate (BHBA) GC/MS 0.5 (P=0.03) 116.9
lysolipid 1-palmitoylglycerophosphocholine LC/MS pos 8.31 (P=0.04) 496.4
1-stearoylglycerophosphocholine LC/MS pos 11.6 (P=0.04) 524.4
2-stearoylglycerophosphocholine LC/MS pos 2.01 (P=0.02) 524.4
1-palmitoylglycerophosphoinositol LC/MS neg 0.48 (P=0.04) 571.3
1-stearoylglycerol (1-monostearin) LC/MS neg 0.48 (P=0.02) 399.4
Sphingolipid Palmitoyl sphingomyelin GC/MS 0.49 (P=0.03) 311.3
cholesterol GC/MS 0.8 (P=0.04) 329.3
nucleotide Purine metabolism, (hypo)xanthine/
inosine containing
Xanthine LC/MS pos 0.67 (P=0.03) 153.1
Hypoxanthine LC/MS pos 0.51 (P=0.04) 135.1
inosine LC/MS neg 0.49 (P=0.02) 267.2
adenosine 3’-monophosphate (3’-aMP) LC/MS pos 0.58 (P=0.02) 348.1
guanosine LC/MS neg 0.5 (P=0.02) 282.1
Purine metabolism, guanine 
containing
cytidine LC/MS pos 0.51 (P=0.02) 244
Pyrimidine metabolism, orotate 
containing
Uracil GC/MS 0.6 (P=0.03) 241
Cofactors and 
vitamins
nicotinate and nicotinamide 
metabolism 
nicotinamide LC/MS pos 0.54 (P=0.01) 123.1
Pantothenate and coa metabolism Pantothenate LC/MS pos 0.44 (P=0.02) 220.1
Riboflavin metabolism Benzoate GC/MS 0.56 (P=0.04) 179
 Xenobiotics chemical glycerol 2-phosphate GC/MS 0.36 (P=0.04) 243
Stachydrine LC/MS pos 0.46 (P=0.006) 144.1
homostachydrine LC/MS pos 0.6 (P=0.008) 158.2
Equol sulfate LC/MS neg 0.51 (P=0.03) 321.2
Abbreviations: Fst-Tg, follistatin transgenic; WT, wild type; Epi, epididymal; LC/MS, liquid chromatography–mass spectrometry; pos, positive; neg, negative; GC/MS, gas 
chromatography–mass spectrometry; SAM, S-adenosylmethionine; BCAA, branched chain amino acid; CoA, coenzyme A.
Table 2 (Continued)
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found to be significantly decreased in both adipose tissues 
obtained from Fst-Tg mice (Tables 2 and 3). 
Omega-3 PUFas
Comparative analysis of omega-3 levels PUFAs between the 
Fst-Tg and WT adipose tissue metabolites display highly 
significant increase in two key PUFAs including docosapen-
taenoate (n3; 22:5n3) (1.42 fold; P=0.006), and docosahexae-
noate (22:6n3) (1.5 fold; P=0.03) selectively in SC adipose 
tissues (Table 3). However, these levels were not statistically 
different in the Epi adipose tissues obtained from WT and 
Fst-Tg groups. These n-3 long chain PUFAs are reported 
to improve obesity-associated metabolic orders including 
chronic inflammation, insulin resistance, and dyslipidemia 
in several studies by directly regulating several aspects of 
lipid metabolism, energy expenditure, and inflammation.37–40 
Future studies will determine the role of Fst in the regulation 
of these additional pathways.
Selective induction of BCAA catabolic 
enzyme expression in Epi adipose tissues 
obtained from Fst-Tg mice
The specific decrease in BCAA observed in Epi tissues of the 
Fst-Tg could be explained either by decreased synthesis or 
by increased catabolism. We therefore, analyzed the expres-
sion levels of BCAT2 that catalyzes the first and reversible 
step in BCAA catabolism as well as components of BCKD 
complex that irreversibly catalyzes subsequent deamination 
steps to generate final BCAA metabolites (Figure 3). We 
found a significant increase in Bcat2 gene (1.8±0.2 fold) 
and BCAT2 protein (1.45±0.24 fold) expression selectively 
in Epi adipose tissues of Fst-Tg mice compared to the WT 
mice (Figure 4A–C). There was no significant change in its 
gene or protein expression in SC adipose tissues (Figure 4D 
and E). Further analysis of key genes of BCKDH complex 
show significant increase in Bckdhb (1.76±0.3 fold), Dbt 
Table 3 Metabolomics analysis (Metabolon Inc.) of SC adipose tissues obtained from 6-weeks-old WT and Fst-Tg mice showing 
relative differences in various metabolites involved in the regulation of key metabolic pathways (n=3).
Super pathway Sub pathway Biochemical name Platform Fst-Tg vs WT-SC 
(fold; P-value)
Mass
amino acids alanine and aspartate 
metabolism
Beta-alanine GC/MS 1.94 (P=0.04) 174
alanine GC/MS 0.53 (P=0.02) 115.9
Tryptophan metabolism 3-indoxyl sulfate LC/MS pos 0.39 (P=0.04) 212
Valine, leucine, and isoleucine 
metabolism
Hydroxyisovaleroyl carnitine LC/MS pos 0.58 (P=0.02) 262.1
carbohydrate aminosugars metabolism erythronate GC/MS 0.37 (P=0.01) 292.1
Fructose, mannose, galactose, 
starch, and sucrose metabolism
Maltose GC/MS 0.55 (P=0.04) 204.1
glycolysis, gluconeogenesis, 
andpyruvate metabolism
glycerate GC/MS 0.59 (P=0.02) 189
3-phosphoglycerate GC/MS 0.49 (P0.01) 299
energy Krebs cycle Succinate LC/MS neg 0.8 (P=0.01) 117.1
Oxidative phosphorylation Phosphate GC/MS 0.64 (P=0.04) 298.9
 lipids  Essential fatty acids Docosapentaenoate (n3 DPa; 22:5n3) LC/MS neg 1.42 (P=0.006) 329.4
Docosahexaenoate (DHA; 22:6n3) LC/MS neg 1.5 (P=0.03) 327.3
Long chain fatty acid Myristate (14:0) LC/MS neg 0.56 (P=0.03) 227.3
Myristoleate (14:1n5) LC/MS neg 0.53 (P=0.002) 225.3
Palmitoleate (16:1n7) LC/MS neg 0.76 (P=0.008) 253.3
Fatty acid, monohydroxy 4-hydroxybutyrate (GHB) GC/MS 0.36 (P=0.03) 233.1
Fatty acid, dihydroxy Propionylcarnitine LC/MS pos 0.71 (P=0.03) 218.2
carnitine metabolism acetylcarnitine LC/MS pos 0.7 (P=0.002) 204.2
inositol metabolism chiro-inositol GC/MS 0.31 (P=0.01) 318.1
glycerolipid metabolism glycerol 3-phosphate (g3P) GC/MS 0.41 (P=0.04) 357.1
lysolipid 1-palmitoylglycerophosphoinositol LC/MS neg 0.53 (P=0.04) 571.3
Sterol/Steroid corticosterone LC/MS pos 0.55 (P=0.02) 347.2
nucleotide Purine metabolism adenine GC/MS 0.16 (P=0.02) 264
Pyrimidine metabolism Pseudouridine LC/MS neg 0.64 (P=0.03) 243.1
 Xenobiotics  Food component/plant Stachydrine LC/MS pos 0.45 (P=0.005) 144.1
homostachydrine LC/MS pos 0.58 (P=0.03) 158.2
Abbreviations: Fst-Tg, follistatin transgenic; WT, wild type; SC, subcutaneous; GC/MS, gas chromatography–mass spectrometry; LC/MS, liquid chromatography–mass 
spectrometry; pos, positive; neg, negative.
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(1.61±0.21 fold), and Dld (1.58±0.06 fold) gene expression 
selectively in Epi adipose tissues of Fst-Tg mice compared to 
WT mice (Figure 4A). Once again, SC adipose tissue display 
no significant difference in any of the BCKDH complex genes 
(Figure 4D). Furthermore, protein expression of BCKDHA 
was also selectively upregulated (1.3±0.16 fold) only in Epi 
adipose tissues (Figure 4B to C) obtained from Fst-Tg mice 
compared to the WT mice but not in SC adipose tissues 
(Figure 4E and F). It is not clear at this point as to why Fst 
selectively upregulates Epi adipose tissue BCAA catabolism 
in Fst-Tg mice; however, it is important to mention that 
Epi adipose tissues are known to play major role in BCAA 
homeostasis because of their larger capacity to catabolize 
BCAAs.41 Effect of Fst overexpression on quantitative gene 
expression profiles of these BCAA catabolizing enzymes 
in differentiating 3T3-L1 Fst cells were also analyzed. 
Our data clearly suggest a small but significant increase in 
Bcat2 (1.45±0.22 fold), Bckdha (1.34±0.08 fold), Backdhb 
(1.43±0.11 fold), Dbt (1.76±0.08 fold), and Dld (1.53±0.07 
fold) (Figure 4G). We also observed that overexpression of 
Fst in C2C12 cells leads to significant induction of key BCAA 
catabolic genes (Figure S3). Therefore, our data suggest low 
but significant upregulation of BCAA catabolizing enzymes 
both in vitro and in vivo and provide putative mechanism for 
the decrease in several of these BCAA levels in Epi tissues 
of Fst-Tg mice (Table 2). 
Upregulation of FGF21/ AdipoQ/ AMPK 
signaling pathway in both epi and Sc 
adipose tissues compared to the WT 
mice 
FGF21/AdipoQ/AMPK pathway is known to regulate key 
metabolic functions including energy homeostasis, glucose 
and lipid metabolism, and insulin sensitivity and has been 
implicated in metabolic diseases including diabetes, obesity, 
and hypertension.42–47 Previously, we had identified AdipoQ, 
Pgc1α, and FGF21 binding partner Klb as differentially 
expressed genes in differentiating Fst-KO MEF cultures 
compared to the WT group, suggesting that AdipoQ/ FGF21 
axis may be a primary target of Fst action during its regula-
tion of adipose tissue metabolic function.7 Since AdipoQ 
has been reported to be a downstream effector of FGF21,42 
a well-known adipose browning and important regulator of 
key metabolic functions,43–46 we explored the potential role of 
FGF21/AdipoQ/pAMPK signaling pathway in eliciting Fst 
metabolic actions in both Epi and SC adipose tissues from 
WT and Fst-Tg mice. We observed significant increase in 
AdipoQ, FGF21, and PGC-1α, proteins as well pAMPK/
AMPK ratio in both Epi and SC adipose tissues obtained from 
Fst-Tg mice compared to the WT control mice (Figure 5A). 
This effect of Fst-induced upregulation of FGF21/AdipoQ/
pAMPK signaling pathway was also confirmed in our in 
vitro studies using differentiated 3T3-L1 cells treated either 
with recombinant Fst protein (0.5 µg/ml) or treatment of cell 
supernatant (500 µl in confluent 3T3-L1 cells on T25 flask) 
from 9-day differentiated 3T3-L1 Fst cells (Figure 5B). We 
have also observed basal expression of AdipoR1 (AdipoQ key 
adipose receptor) and SirT1 in differentiated 3T3-L1 cells, 
which were induced following treatment of these cells either 
with recombinant Fst protein or cell supernatant from 3T3-
L1 Fst cells (Figure 5B). We next analyzed gene expression 
profile of key FGF21 target genes (Egr1, c-Fos), receptors 
(Fgfr1, Fgfr2, and Fgfr3), and its catalytic partner Klb along 
with Pgc1α in both Epi and SC adipose tissues from WT and 
Fst-Tg mice (Figure 5C and D). 
We found significant increase in Fgf21 (Epi: 1.4±0.24 
fold, P≤0.05; SC: 3.4±0.24 fold), Egr1 (Epi: 3.48±0.16 
fold; SC: 11.25±1.37 fold), c-Fos (Epi: 3.55±0.5 fold; SC: 
1.8±0.14 fold), Fgfr1 (Epi: 1.87±0.07 fold; SC: 3.25±0.49 
Figure 3 Schematic presentation of key enzymes and metabolites involved in branched-chain amino acid (valine, isoleucine, leucine) catabolic pathways. 
Abbreviations: BCAT, branched chain amino transferase; BCKD, branched chain α-keto acid dehydrogenase (complex).
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Figure 4 Analysis of key genes and proteins involved in BCAA catabolic pathways. (A) Quantitative gene expression analysis of mitochondrial Bcat2 and key BCKDH 
complex enzymes in Epi adipose tissues isolated from male 10-week-old WT and Fst-Tg mice. Western blot analysis using 100 µg total cell lysates (B) and densitometric 
quantitation (C) of BCAT2 and BCKDHA proteins in Epi adipose tissues isolated from male WT and Fst-Tg mice. (D) Real-time quantitative gene expression analysis 
of mitochondrial Bcat2 and key BCKDH complex enzymes in SC adipose tissues isolated from male WT and Fst-Tg mice. Western blot analysis (E) and densitometric 
quantitation (F) of BCAT2 and BCKDHA proteins in SC adipose tissues isolated from male WT and Fst-Tg mice. Data are expressed as mean ± SD. *P≤0.05 (n=3). (G) real-
time quantitative gene expression analysis of mitochondrial Bcat2 and key BCKDH complex enzymes in differentiating 3T3-L1 and 3T3-L1 Fst cells. *P≤0.05, **P≤0.01 (n=3). 
Abbreviations: WT, wild type; Fst-Tg, follistatin transgenic; Epi, epididymal; BCAT, branched chain aminotransferase; BCKDHA, branched chain ketoacid dehydrogenase; 
BCAA, branched chain amino acid; SC, subcutaneous.
0.0
0.0
0.5
1.0
*
*1.5
2.0
Bc
at2
Bc
kd
ha
Bc
kd
hb Db
t
Dl
d
Bc
kd
k
Bc
at2
Bc
kd
ha
Bc
kd
hb Db
t
Dl
d
Bc
kd
k
Bc
at2
Bc
kd
ha
Bc
kd
hb Db
t
Dl
d
BC
AT
2
BC
KD
HA
BC
AT
2
BC
KD
HA
0.5
1.0
1.5
0.0
0.5
1.0
1.5
2.0
A B C
D
G
E F
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
0.0
0.5
1.0
1.5
R
el
at
iv
e 
pr
ot
ei
n 
ex
pr
es
si
on
R
el
at
iv
e 
pr
ot
ei
n 
ex
pr
es
si
on
*
*
*
**
*
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
WT Epi
Fst-Tg Epi
WT SC
Fst-Tg SC
SC
WT Fst-Tg
BCAT2
BCKDHA
-actin
WT Epi
Fst-Tg Epi
WT SC
3T3-L1
3T3-L1 Fst
Fst-Tg SC
* * *
* Epi
BCAT2
BCKDHA
-actin
WT Fst-Tg
 
D
ia
be
te
s,
 M
et
ab
ol
ic 
Sy
nd
ro
m
e 
an
d 
O
be
sit
y:
 T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
64
.1
47
.4
8.
86
 o
n 
14
-A
pr
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
77
Fst therapy for metabolic diseases
fold), Fgfr2 (SC: 7.56±1.6 fold), Fgfr3 (SC: 7.14±1.27 fold), 
Klb (SC: 2.93±0.6 fold) and Pgc1a (Epi: 2.4±0.29 fold; SC: 
6.35±1.8 fold), gene expression in Fst-Tg compared to the 
WT adipose tissues (Figure 5C and D). These differences 
in FGF21-associated genes and protein were also evident 
in other metabolic tissues including interscapular BAT and 
liver (Figure S4A–C). Our data, therefore suggest a role for 
FGF21/AdipoQ/pAMPK signaling pathway in regulating key 
metabolic targets of Fst in both Epi and SC adipose tissues. 
Discussion
We have recently identified Fst as a novel inducer of brown 
adipose characteristics and a regulator of key lipid and 
energy metabolism.7 Fst promotes browning of Epi and 
SC adipose tissues in Fst-Tg mice by targeting p38MAPK/
ERK1/2 signaling pathways.8 Agents promoting adipose 
browning have recently been reported to provide significant 
therapeutic advantage for the treatment of obesity and related 
metabolic diseases because of their unique energy burning 
capacity.10,11,14 Fst-Tg mice have previously been reported to 
have significantly increased body weight and muscle mass 
because of muscle-specific overexpression of Fst, a well-
known inducer of muscle mass.3 Our previous studies using 
these Fst-Tg male mice suggested that irrespective of the 
site of Fst production increased systemic Fst levels could 
significantly impact the metabolic outcomes of distant tis-
sues, including both Epi and SC adipose tissues via increased 
adipose browning.8 
In the present study, using Fst-Tg mice and 3T3-L1 Fst 
cells, we have applied a comprehensive set of lipidomics and 
biochemical analysis tools to gain a deeper understanding 
of key metabolic targets of Fst both in vivo and in cultured 
adipocytes. Our data demonstrate that despite having sig-
nificantly increased body weight, the abdominal fat volume 
of Fst-Tg mice was significantly lower compared to the 
age-matched control WT mice, suggesting a role for Fst in 
regulating both muscle and fat mass. A strong relationship 
between glucose and lipid metabolism has been demonstrated 
in several studies.48–50 Increased lipolysis followed by increase 
in circulating FFAs in fasted state results in augmented 
FA oxidation to provide energy. Under these conditions, 
glucose oxidation is reduced partly because of the gen-
eration of FA oxidation byproducts. In addition, consequent 
accumulation of bioactive lipid species during obese states 
is known to interfere with insulin signaling.51 Since key 
metabolic characteristics including improved glucose clear-
ance rate and serum lipid profiles observed in Fst-Tg mice 
could be confounded by reciprocal changes in muscle and 
fat content in these mice, we assessed the effect of Fst on 
key metabolites in adipose tissues and in differentiated 3T3-
L1 Fst cells to dissect out its precise role in modulating key 
metabolic mediators. 
Lipidomic profiling has been used effectively to analyze 
global lipid alterations during obesity and other metabolic 
diseases as well as in several animal studies.52–54 Our lipido-
mics data show significant decrease in several lipid metabo-
lites including several TG, FA, PC, and PE of varying chain 
lengths in 3T3-L1 Fst cells compared to the 3T3-L1 cells. 
Levels of several LPCs which are reported to be decreased 
in obese patients30,31 were found to be significantly higher 
in Fst overexpressing cells. Several studies using liver and 
serum samples from obesity-resistant and obesity-prone mice 
on high fat diet and in obese subjects have shown similar 
changes in many of these lipid metabolites.52,55
In one or both adipose tissues from Fst-Tg mice, our data 
demonstrates that several amino acids including BCAA are 
less abundant. Many BCAA catabolites en route to TCA 
cycle including alanine, and several C3 and C5 acylcarnitines 
including isobutyl carnitine (valine catabolism intermedi-
ate), isovalerylcarnitine (leucine catabolism intermediate), 
and propionylcarnitine (isoleucine and valine catabolism 
intermediate) were also less abundant in Fst-Tg in one or 
both adipose tissues. Furthermore, expression levels of two 
key BCAA catabolic proteins BCAT2 and BCKDHA were 
significantly higher specifically in Fst overexpressing Epi 
adipose tissues, suggesting a predominant role for BCAA 
catabolic pathway in adipose tissues metabolism in Fst-Tg 
mice. Significantly, increased levels of tyrosine has been 
reported in several studies including obese subjects.17,56 The 
association between BCAA and amino acid with insulin 
resistance and type 2 diabetes have been noted in multiple 
studies over the years.33,34 Data obtained from our current 
findings therefore, strongly suggest that Fst could signifi-
cantly inhibit local production of BCAA associated metabo-
lites in adipose tissues and elicit metabolic advantage. A 
recent metabolic profiling identified significant association 
between visceral fat lactate levels and markers of type 2 
diabetes, and insulin resistance, suggesting a metabolic link 
between perturbed lactate levels in visceral fat and cardio-
metabolic diseases.57 Increased mitochondrial activity and 
FA oxidation in Fst-Tg mice could reduce glycolysis lead-
ing to reduced lactate levels. Our metabolomics data in Epi 
adipose tissues from Fst-Tg mice demonstrate significant 
lower lactate levels compared to the WT along with several 
other carbohydrate metabolites, further suggest that Fst 
may favorably modulate overall carbohydrate metabolism 
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and provide protection against these diseases. A detailed 
analysis of these sugar metabolites and their possible role 
needs to be investigated in future to assess the potential 
therapeutic use of Fst specifically in the context of diabetic 
atherosclerosis and hyperglycemia. Several studies includ-
ing global metabolomic profiling of childhood obesity58 and 
high-fat-diet induced metabolic changes59 have identified 
lysolipids as important metabolic regulators. Our data identi-
fied significantly higher levels of three major lysolipids that 
are reported to be significantly lower in obese child in Fst 
Figure 5 Effect of Fst overexpression on AdipoQ/FGF21/pAMPK pathway and FGF21 target genes. Western blot analysis of key proteins in Epi and SC adipose tissues from 
WT and Fst-Tg mice (A), and recombinant Fst protein (0.5 µg/ml) or Fst-enriched supernatant treatment of differentiated 3T3-L1 cells (B) using 100 µg of total tissue or cell 
lysates. Real-time quantitative gene expression analysis of FGF21, its receptors (Fgfr1-r3) and target genes in Epi (C), and Sc (D) adipose tissues obtained from 10-week old 
WT and Fst-Tg mice. Data are expressed as mean ± SD. *P≤0.05, **P≤0.01, and ***P≤0.001 (n=3). 
Abbreviations: WT, wild type; Fst-Tg, follistatin transgenic; DM, differentiation medium; AdipoQ, adiponectin; FGF, fibroblast growth factor; AMPK, AMP-activated protein 
kinase; PGC, peroxisome proliferator-activated receptor-gamma coactivator; SirT1, sirtuin1; GADPH, glyceraldehyde 3-phosphate dehydrogenase; Epi, epididymal; SC, 
subcutaneous.
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overexpressing Epi adipose tissues.58 However, the levels of 
1-palmitoylglycerophosphoinositol was found to be lower in 
both adipose tissue depots from Fst-Tg mice as compared to 
the WT group. Epi adipose tissues from Fst-Tg mice display 
significantly lower levels of betahydroxybutyric acid, an 
end-product of FA β-oxidation which is often associated 
with metabolic syndrome. In general, our metabolomics data 
show a clear pattern of favorable changes in key metabolites 
that have been implicated in several metabolic conditions and 
warrants future studies to explore in detail the therapeutic 
benefits of Fst. 
In our previous studies, we had identified Fst as a novel 
inducer of adipose browning characteristics both in in vitro 
cultures of differentiating cells under adipogenic conditions 
and in adipose tissues from Fst-Tg mice. To explore the pos-
sible connection between Fst-induced adipose browning and 
observed metabolic alterations in adipose tissues in Fst-Tg 
mice, we assessed the possible role of FGF21/AdipoQ/pAMPK 
axis, which is known to regulate key metabolic functions 
including energy homeostasis, glucose and lipid metabolism 
and insulin sensitivity.42–47 While adipose-derived FGF21 can 
act in an autocrine/paracrine manner to increase thermogenic 
genes and adipose browning, it is also known to improve lipid 
profiles and influence glucose homeostasis as well as insulin 
sensitivity. FGF21 is reported to rapidly and robustly stimulate 
AdipoQ secretion.44 AdipoQ is a key target of Fst in differen-
tiating MEF7 and reported to mediate the systemic effects of 
FGF21 in regulating energy metabolism and exerting its gly-
cemic and insulin sensitizing effects.42 Furthermore, AdipoQ 
has also been shown to correct altered BCAA metabolism 
caused by high-fat diet in AdipoQ KO mice.59 Our data in both 
adipose tissues and 3T3-L1 cells treated either with recombi-
nant Fst protein or cell supernatant highly enriched in secreted 
Fst from Fst overexpressing 3T3-L1 Fst cells display robust 
activation of FGF21/AdipoQ/pAMPK signaling pathway. Fst 
overexpression was associated with significant upregulation of 
FGF21 receptors, and its downstream targets in both adipose 
tissue depots compared to the WT group. Levels of AMPK 
phosphorylation was also significantly higher in both adipose 
tissues and in Fst treated 3T3-L1 cells. While AMPK activa-
tion has been known to inhibit acetyl CoA carboxylase, a key 
player in FA synthesis;60 decreased AMPK levels in adipocytes 
are known to promote insulin resistance and hepatic steatosis 
through brown and beige adipose tissue function.61 Our find-
ings using these Fst-Tg mice thus clearly supports a cross-talk 
between muscle and adipose tissues resulting in modulation of 
key browning and associated metabolic characteristics. Recent 
studies have identified several myokines including myostatin, 
FGF21, IL-4, IL-6, IL-7, irisin, and sarcolipin among several 
others in regulating key metabolic characteristics in adipose 
tissues.62–65 Our findings, therefore, suggest for the first time 
that Fst released from skeletal muscle could directly target 
FGF21/AdipoQ/pAMPK signaling pathway and influence the 
levels of adipose tissue metabolites involved in regulating key 
metabolic processes implicated in obesity, type 2 diabetes, and 
insulin resistance. 
Abbreviations
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AMPK, AMP-activated protein kinase
ANOVA, analysis of variance
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FA, fatty acid
FFA, free fatty acid
FGF, fibroblast growth factor 
Fst, follistatin
Fst-KO, Fst knockout
Fst-Tg, Fst transgenic
LPC, lysophosphatidylcholine 
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Supplementary materials
Figure S1 (A) Vector map of PiggyBac-CMV-Fst-Puro. (B) Polymerase chain reaction analysis confirming Fst insertion in the PiggyBac-CMV-Fst-Puro construct.  
Abbreviation: Fst, follistatin.
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Figure S2 Analysis of Mup1 expression in liver tissues from WT and Fst-Tg mice. Immunohistochemical analysis (A) and quantitative image analysis (B) of tissues sections. 
integrated optical density (immunopositive area × intensity). Quantitation was performed using 20 images from 4 different areas as described previously.1–3 Analysis of Mup1 
protein (C) and gene expression (D) by Western blot and quantitative real-time polymerase chain reaction analysis using standard procedures. Data are expressed as mean 
± SD. *P≤0.05; **P≤0.01. 
Abbreviations: WT, wild type; Fst-Tg, follistatin transgenic; IHC, immunohistochemistry; Mup, major urinary protein; IOD, integrated optical density; GADPH, 
glyceraldehyde 3-phosphate dehydrogenase.
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Figure S3 Real-time quantitative polymerase chain reaction analysis of C2C12 and Fst overexpressing (C2C12-Fst) myoblast cells to compare gene expression profiles of 
key BCAA metabolizing enzymes. Data are expressed as mean ± SD. *P≤0.05; **P≤0.01 (n=3). 
Abbreviations: Fst, follistatin transgenic; BCAA, branched chain amino acid.
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Figure S4 Analysis of FGF21-associated markers in BAT and liver tissues from 6-weeks-old male WT and Fst-Tg mice. (A) Western blot analysis of FGF21, PGC-1α, and 
il-6 proteins. (B to C) Quantitative gene expression analysis of FGF21, its receptors (Fgfr1-3), and beta-klotho (Klb) in BAT and liver tissues from WT and Fst-Tg mice. Data 
are expressed as mean ± SD. *P≤0.05; **P≤0.01; ***P≤0.001 (n=3). 
Abbreviations: WT, wild type; Fst-Tg, follistatin transgenic; FGF, fibroblast growth factor; PGC, peroxisome proliferator-activated receptor-gamma coactivator; IL, 
interleukin; GADPH, glyceraldehyde 3-phosphate dehydrogenase; BAT, brown adipose tissue.
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